Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies

Interleukin-15 (IL-15) monotherapy substantially increases the number and activity of natural killer (NK) cells and CD8(+) T cells but has not produced clinical responses. In a xenograft mouse model, IL-15 enhanced the NK cell–mediated antibody-dependent cell cytotoxicity (ADCC) of the anti-CD52 ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Miljkovic, Milos D., Dubois, Sigrid P., Müller, Jürgen R., Bryant, Bonita, Ma, Elaine, Conlon, Kevin C., Waldmann, Thomas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898617/
https://www.ncbi.nlm.nih.gov/pubmed/35475910
http://dx.doi.org/10.1182/bloodadvances.2021006440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898617/
https://www.ncbi.nlm.nih.gov/pubmed/35475910
http://dx.doi.org/10.1182/bloodadvances.2021006440

Ejemplares similares